Stay updated on Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.
Latest updates to the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.3.2 is now shown in the page footer, replacing v3.3.1; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check21 days agoChange DetectedThe page history shows a new 'Revision: v3.3.1' entry added and the previous 'Revision: v3.2.0' entry removed, reflecting a minor maintenance update to revision labeling and not altering listed study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check29 days agoChange DetectedRemoved the government funding and operating status banner from the top of the page. The rest of the study record content remains unchanged.SummaryDifference0.6%
- Check43 days agoChange DetectedThe new version adds a termination notice for the study, noting that AstraZeneca stopped enrollment and Part 2 was not initiated. It also updates the study status and enrollment details.SummaryDifference0.1%
- Check71 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference11%
- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.3%
Stay in the know with updates to Subcutaneous Durvalumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Durvalumab in Lung Cancer Clinical Trial page.